Completed PHASE3 INTERVENTIONAL 2-arm NCT00027300

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis

Sponsor: Biogen

Conditions Multiple Sclerosis, Relapsing-Remitting

Interventions Natalizumab Placebo

Updated 7 times since 2017 Last updated: Jan 5, 2017 Started: Nov 30, 2001 Primary completion: Nov 30, 2004 Completion: Jan 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Multiple Sclerosis, Relapsing-Remitting and is currently completed. Biogen leads this study, which shows 7 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biogen
Elan Pharmaceuticals

Data source: Biogen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Allentown, United States , Amsterdam, Netherlands , Berkeley, United States , Bochurn, Germany , Brno, Czechia , Bruges, Belgium , Bydgoszcz, Germany , Dallas, United States , Davis, United States and 38 more locations